Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen



Status:Terminated
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/17/2019
Start Date:August 26, 2010
End Date:December 26, 2018

Use our guide to learn which trials are right for you!

A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment

The purpose of this study is to evaluate the safety and efficacy of ofatumumab and
bendamustine combination therapy in patients with indolent B-cell NHL that did not respond to
rituximab or a rituximab-containing regimen during or within 6 months of the last rituximab
treatment.

Ofatumumab is an anti-CD20 monoclonal antibody shown to have monotherapy activity in patients
with follicular lymphoma that has relapsed following rituximab-containing therapy.
Bendamustine was approved by FDA for the treatment of in patients with indolent B-cell
Non-Hodgkin's Lymphoma (NHL) that did not respond to rituximab or a rituximab-containing
regimen during or within 6 months of the last rituximab treatment.

Biologics have demonstrated enhanced efficacy when added to chemotherapeutic combinations in
the frontline treatment for indolent NHL. The combination of ofatumumab and bendamustine may
provide additional clinical benefit and efficacy to those who no longer respond to rituximab
or rituximab-containing regimens.

The objective of this study is to determine the effect of ofatumumab and bendamustine
combination therapy in patients with indolent B-cell NHL that did not respond to rituximab or
a rituximab-containing regimen during or within 6 months of the last rituximab treatment.

Inclusion Criteria:

- Indolent lymphoma including Grades 1-3a follicular, small lymphocytic,
lymphoplasmacytic, and marginal zone lymphoma; Stages III-IV, or bulky disease, Stage
II. Tumor verified CD20+ and CT imaging done at screening verifying disease

- Indolent B-cell NHL that remains stable or unresponsive during or within 6 months of
treatment with rituximab or a rituximab-containing regimen

- Indolent lymphoma including grades 1-3a follicular, small lymphocytic,
lymphoplasmacytic, and marginal zone lymphoma; stages III-IV, or bulky disease stage
II (i.e. as any single mass > 5 cm in any direction)

- ECOG Performance Status of 0, 1, or 2

- Life expectancy of at least 6 months

- 18 years or older

- Signed, written informed consent

Exclusion Criteria:

- Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to
aggressive lymphoma

- Previous allogeneic stem cell transplant

- Previous autologous stem cell transplant, fludarabine therapy, or radioimmunotherapy
in the past 12 months

- Previous external beam radiation therapy to the pelvis. Previous external beam
radiation therapy for bony disease to the cranium, mediastinum, and axilla, or to two
or to more than 3 vertebral bodies

- High dose steroids greater to or equal to 60 mg prednisone/day (or equivalent) within
3 months of randomization. No more than 10 mg prednisone (or equivalent) daily at the
time of randomization

- Prior bendamustine treatment within 1 year of randomization not resulting in a CR or
PR for at least 6 months

- Treatment with anti-CD20 monoclonal antibody within 3 months of randomization

- Known CNS involvement of indolent lymphoma

- Other past or current malignancy. Subjects free of malignancy for at least 5 years or
have history of definitively treated non-melanoma skin cancer, or successfully treated
in situ carcinoma, are eligible

- Chronic or current active infectious disease requiring systemic antibiotics,
antifungal, or antiviral treatment

- Clinically significant cardiac disease

- History of significant cerebrovascular disease or event with significant symptoms

- Positive serology for Hepatitis B

- Current active liver or biliary disease (except Gibler's syndrome or asymptomatic
gallstones, liver metastases, or otherwise stable chronic liver disease)

- Known HIV positive

- Abnormal/inadequate blood values, liver and kidney function

- Current participation in other clinical study

- Inability to comply with the protocol activities

- Lactating or pregnant women or female patients of child-bearing potential (or male
patients with such partners) not willing to use adequate contraception
We found this trial at
19
sites
Philadelphia, Pennsylvania 19102
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Atlanta, Georgia 30322
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Beverly Hills, California 90211
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Capital Federal, Buenos Aires
?
mi
from
Capital Federal,
Click here to add this to my saved trials
Charleston, South Carolina 29407
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Coeur d'Alene, Idaho 83814
?
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
Danville, Pennsylvania 17822
?
mi
from
Danville, PA
Click here to add this to my saved trials
Detroit, Michigan 48202
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Mineola, New York 11501
?
mi
from
Mineola, NY
Click here to add this to my saved trials
Morgantown, West Virginia 26506
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
Nashville, Tennessee 37205
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Palm Springs, California 92262
?
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Richmond, Virginia 23249
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Rochester, New York 14615
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Saint Louis, Missouri 63128
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Seattle, Washington 98103
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Silver Spring, Maryland 20901
?
mi
from
Silver Spring, MD
Click here to add this to my saved trials
Tucson, Arizona 85745
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Washington, District of Columbia 20007
?
mi
from
Washington,
Click here to add this to my saved trials